MIAMI, July 29, 2020 /PRNewswire/ --An FDA Safety Panel discussion will be held virtually by the American Academy of Stem Cell Physicians (AASCP) Aug.1-3, 2020, with guest speakerFDA Director Dr. Peter Marks. This is a highly anticipated session which will discuss the growing safety concerns of the industry.
Cell and gene therapies are expected to represent one of the biggest advances in medical treatments since the introduction of monoclonal antibodies. Cell therapies are having a major impact on hematological malignancies, while gene therapy programs for rare and non-rare diseases could potentially benefit some 2.4 billion patients worldwide
Be the Match: Every three minutes, someone is diagnosed with a life-threatening blood cancer or blood disease, such as leukemia, lymphoma or sickle cell disease, and you might be able to help. For those thousands, a cure exists, though about 70% of patients dont find it within their own families. Thats why the College of the Canyons Biology Club is partnering with Be The Match to host a drive-in community registry event, where the community is invited to register to be a potential match for someone in need of a life-saving stem cell transplant through a simple swab test.
XconomyBoston AlloVir is the latest biotech company to go public, raising about $276.3 million to pull its cell therapies off the shelf and run multiple clinical trials testing them in stem cell and organ transplant patients. On Thursday, Cambridge, MA-based AlloVir (NASDAQ: ALVR)priced its offering of 16.25 million shares at $17 apiece, the midpoint of its targeted $16 to $18 per share price range.
Doctor Photo courtesy of Getty Images MISSION, Kan., July 28, 2020 (GLOBE NEWSWIRE) -- (Family Features) Despite progress in treating lung cancer, it is the leading cause of cancer deaths and impacts communities across the United States. The most common form of lung cancer is non-small cell lung cancer (NSCLC).
Scientists at the University of WisconsinMadison have published a proof-of-concept method to correct an inherited form of macular degeneration that causes blindness, and that is currently untreatable.
Drug Target Review explores some of the newest oncologic drug targets, including those for glioblastoma, lung cancer and breast cancer.
Two and a half years ago, a study published in Science Advances detailed how the gene editing tool CRISPR/Cas-9 repaired genetic mutations related to Duchenne Muscular Dystrophy (DMD).
Mantapond Ittarat,1,2 Thanapong Somkijrungroj,2,3 Sunee Chansangpetch,2,4 Pear Pongsachareonnont2,3 1Surin Hospital and Surin Medical Education Center, Department of Ophthalmology, Suranaree University of Technology, Surin, Thailand; 2Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand; 3Vitreoretinal Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 4Glaucoma Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand Correspondence: Pear Pongsachareonnont Department of Ophthalmology, Faculty of Medicine 1873 Rama IV Road, Patumwan, Bangkok 10330, ThailandTel +66-2256-4142Fax +66-2-252-8290Email pear.p@chulahospital.org Purpose: To summarize current surgical techniques for treating primary macular holes (MHs).Methods: We reviewed publications detailing surgical approaches to primary MHs, briefly described their protocols, and outlined their results.Results: Currently, the technique for primary MH repair is pars plana vitrectomy, removing the posterior cortical vitreous, stripping the epiretinal membranes, and ending with intraocular gas tamponade.
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced it has been awarded a five-year tender by the Hong Kong Red Cross Blood Transfusion Services (BTS) for INTERCEPT Blood System for platelets.
Recent Comments